ClinicalTrials.gg
RecruitingNCT07193589Updated Feb 4, 2026

A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis

A Phase 2 interventional study of The high-dose group of ZL-82 tablets and The low-dose group of ZL-82 tablets in Atopic Dermatitis, sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
125th of 190
111 · median 164
Started
2026
with 31 others
Phase 2
58 of 206
16 open now
Primary completion
2027-12
later than 59 of 81 live
Registered
144th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 125th largest by planned enrollment of the 190 interventional ones that give a count, is one of 32 that started in 2026, is one of 58 in phase 2, reaches primary completion later than 59 of the 81 other live ones, and was the 144th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This clinical trial aims to explore whether the drug ZL-82 tablets can be used to treat moderate to severe atopic dermatitis in adults, and to understand the safety and tolerability of the drug. The main questions that the trial intends to answer are: Can ZL-82 tablets alleviate the Eczema Area and Severity Index (EASI) score of patients? What physical problems will patients have after taking ZL-82 tablets? The researchers will compare ZL-82 tablets with placebo (a substance with a similar appearance but without drug components) to observe whether ZL-82 tablets can be used to treat moderate to severe atopic dermatitis. Participants need to take ZL-82 tablets or placebo every day for 16 weeks, and visit the hospital for a check-up every two weeks; record their own symptoms and the percentage change of EASI score relative to the baseline.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • ZL-82
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female individuals aged 18 years and above and 75 years and below (inclusive of the threshold value, based on the date of signing the ICF), with >= 19 kg/m2.
  2. Participants are fully informed of the purpose and requirements of this trial, and voluntarily sign the form.
  3. According to the Hanifin \& Rajka diagnostic criteria (≥ 3 out of 4 main 4, >= 3 out of 23 secondary symptoms, see Appendix 1), diagnosed as AD by the investigators, and with a history of AD for >= 1 year before screening.

4 . The definition of moderate to severe atopic dermatitis during screening and baseline period is as follows:

  1. IGA score of 3 or 4;
  2. EASI score >= 16;
  3. Average peak pruritus NRS score >= 4 in the past week (Note: The NRS average value is the average of the maximum NRS score of pruritus intensity over 7 consecutive days before baseline, with a score range of 0-10 for each day. At least 4 days of scores are required for the calculation of the average score);
  4. BSA (body surface area) affected by AD >= 10% (BSA: body surface area, in this trial, BSA is based on the average human body surface area of 1.6 m2); 5. Participants who have been treated with local drugs, calcineurin inhibitors, or phototherapy within the past 6 months, and whose medical history indicates inadequate response, no response, or intolerance to these treatments, or who have medical for such treatments (treatment duration ≥ 4 weeks), and who require systemic treatment to control the disease, should be selected. Note: For stable treatment response that is insufficient when using local drugs (such as moderate-to-high potency topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)), insufficient response is defined as participants receiving treatment for the recommended duration or the maximum recommended duration as per the instructions, but failing to achieve and maintain disease remission (corresponding to IGA score = 0 [clear] - 2 [mild]).

    6. Use a mild moisturizing agent (moisturizing cream) at a stable dose twice a day for at least 7 consecutive days before the first day of administration, and agree to continue using it during the study.

Exclusion criteria

Exclusion Criteria:

  1. Allergy to the test drug or any component thereof, or allergy or intolerance to other oral Janus kinase (JAK) inhibitors.
  2. Use of any of the following drugs or treatments:

    a. Within 1 month before the baseline, received other oral JAK inhibitor treatment, or had a lack of efficacy or intolerance to other oral JAK inhibitors, including but not limited to baricitinib, upadacitinib, abrocitinib, etc.; b. Within 6 weeks before the baseline, used upadilunab/spicibaydin; c. Within 3 months before the baseline (or within 5 drug half-lives, whichever is longer), used other systemic biological agents known or potentially affecting AD other than dupilumab (such as IL-13 receptor antibody [crizorilumab], IL-31Rα antibody [nimotuzumab] etc.); d. Within 1 week before the baseline, used any AD topical treatment: TCS, TCI, PDE-4 inhibitor, JAK inhibitor, traditional Chinese medicine / Chinese patent medicine, herbal medicine, etc.; e. Within 4 weeks before the baseline (or within 5 half-lives, whichever is longer), used any systemic treatment for AD: (such as cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, etc.), , PDE-4 inhibitor, etc.; f. Within 4 weeks before the baseline received any systemic treatment for AD or other inflammatory diseases, common AD herbal medicine preparations or Chinese patent medicines; g. Within 4 weeks before the baseline received phototherapy (narrow-band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + ultraviolet A [PUVA]), sunbed or any other light-emitting device treatment; h. Within 6 months before the baseline received allergen-specific immunotherapy; i. Within 2 weeks before the baseline or within 5 half-lives of the drug (whichever is longer), systemically used (or expected to be needed throughout the study period) strong or moderate inhibitors or inducers of cytochrome P450 (CYP) (see Appendix II); j. Within 2 weeks before the baseline or within 5 half-lives of the drug (whichever is longer), systemically used (or expected to be needed throughout the study period) P-glycoprotein (P-gp) inhibitors (see Appendix II); k. Had received lymphocyte depletion therapy before (such as: alegrucilunab, anti-CD4 drugs, cladribine, rituximab, omalizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, darzalex); l. Within 3 months before the baseline or within 5 half-lives of the drug (if known, whichever is longer), received any treatment in clinical studies of drugs or medical devices, or was currently enrolled in another interventional study.

  3. Individuals with a history of major diseases: This includes but is not limited to those with a history of diseases in the digestive system, cardiovascular system, respiratory system, musculoskeletal system, endocrine system, nervous and mental system, hematological system, immune system disorders, thromboembolic diseases (or individuals at high risk of thromboembolism), and metabolic abnormalities, or those who have undergone major surgeries, or any other diseases or physiological conditions that the investigator deems may affect the trial results.
  4. Family Planning: a. Pregnant or lactating women; b. Throughout the entire study period, all participants or their spouses (or partners) who have reproductive capacity must ensure to take effective measures from the moment of signing the form until 90 days after the last administration of the drug (contraceptive measures and requirements are detailed in Appendix III); c. Those who plan to donate eggs or sperm during the trial period and within 3 months after the last administration.
  5. Those who have a history of malignant tumors in the past, including solid tumors and hematological (excluding basal cell carcinoma and cutaneous squamous cell carcinoma that have been removed or cured).
  6. Those who have undergone major surgical procedures within 4 weeks before screening or are scheduled to undergo such procedures during the screening period.
  7. Those whose surface antigen or hepatitis B core antibody (except for HBV DNA results within the normal range) is positive, antibody (except for HCV RNA results within the normal range) is positive, antibody is positive, or Treponema pallidum antibody is positive (excluding those with negative RPR/TRUST test results).
  8. Participants should have resting systolic blood pressure (SBP) \< 90 mmHg and/or diastolic blood pressure (DBP) \< 55 mmHg before the first administration. Participants with hypertension (SBP >= 160 mmHg, DBP >= 100 mmHg) treated with two or more antihypertensive drugs but with poor control, and those with severe sleep apnea and other diseases, and those judged by the investigators to have conditions that may interfere with the clinical trial results or affect the safety of the participants.
  9. 12-lead before screening and before the first administration suggests that the PR interval > 200 msec, heart rate \< 55 bpm, and corrected Fridericia (QTcF) >= 450 ms (for males), and >= 470 ms for females. 10. Participants with a history of severe cardiovascular and cerebrovascular diseases and poor control, including myocardial infarction, unstable angina pectoris, congestive heart failure, congenital heart disease, stroke or ; and those with bleeding tendencies, or who have had intracerebral hemorrhage within the past 1 year.

11. Those with any of the following medical histories:

a. Symptoms of bradycardia or related medical history; b. Second or third degree atrioventricular block; c. Cardiac arrest duration > 3 seconds; d. History of sick sinus syndrome or neurocardiac syncope. 12. Those with a history of uncontrolled diabetes (defined as > 9%). 13. Those with any systemic disease that may affect the evaluation of the trial results or active other skin diseases (such as psoriasis, lupus erythematosus, Netherton syndrome, chronic actinic dermatitis, dermatitis herpetiformis), or those with scars, freckles, tattoos, obvious pigmentation and other factors that may affect the evaluation of skin lesions at the affected sites.

14. Those with >= 2 grade peripheral neuropathy according to V5.0 during screening, and those with any significant neurological dysfunction remaining.

15. Those with a history of current active primary or secondary immunodeficiency diseases.

16. Those with previous disseminated herpes zoster or herpes simplex. 17. Those with a history of significant pulmonary diseases such as , pulmonary fibrosis, severe or poorly controlled asthma (except for mild intermittent asthma that does not require routine maintenance treatment).

18. Select patients who need intravenous antibiotics for hospitalization within the past 30 days or who need oral antibiotic treatment for active bacterial, fungal, viral, mycobacterial infections or other infections within the past 14 days before screening.

19. Select patients who have received any live or attenuated vaccines within the past 30 days before screening or who plan to receive any live or attenuated vaccines during the study period or within 30 days after the last administration.

20. Select patients who have a history of active tuberculosis within the past 1 year before screening or who have a positive tuberculosis test result within the past 1 month before screening. These are defined as:

a. Have a history of active tuberculosis infection and no evidence of clinical cure; b. Have imaging evidence (such as chest CT) indicating active tuberculosis in the subject at the time of screening; c. Have suspicious tuberculosis symptoms that cannot be excluded by the investigator's assessment (such as low fever, cough, night sweats, weight loss, etc.); d. Latent tuberculosis infection (LTBI): Have a positive tuberculosis test result during the screening period, but no clinical symptoms or signs of active tuberculosis; Detection methods include but are not limited to T-spot test, QuantiFERON-TB Gold test, PPD test. If the subject has started LTBI preventive treatment according to the guideline-approved protocol before randomization and has been treated for at least 1 month, the subject is eligible. To continue the study, the subject must agree to complete the recommended treatment course for LTBI; e. The result of the tuberculosis test: If the result of the first test is uncertain, a second test should be conducted. If the retest result is still uncertain, the subject should be excluded from this study. If the retest is positive, the subject should receive LTBI treatment. If the retest is negative and does not meet other tuberculosis exclusion criteria, the subject is eligible.

21. During the screening visit, abnormal results of blood routine tests were screened (repeated tests could be conducted for verification, and the decision was made independently by the researchers). The abnormalities included, but were not limited to:

a. White blood cell count \< 3.5 × 10\^9/L; b. \< 1.5 × 10\^9/L; c. Lymphocyte count \< 0.8 × 10\^9/L; d. count \< 100 × 10\^9/L; e. \< 9.0 g/dL. 22. During the screening visit, abnormal results of blood biochemistry (repeated tests are allowed for verification, and the determination is made independently by the researchers), including but not limited to:

  1. Total > 1.5 × (ULN);
  2. > 1.5 × ULN;
  3. ALT > 1.5 × ULN. 23. With moderate or end-stage renal function impairment, including but not limited to:

a. Estimated \< 60 mL/min/1.73 m2; b. Estimated rate \< 60 mL/min; c. Creatinine level > 1.4 mg/dL or 123 μmol/L (for female participants); d. Creatinine level > 1.6 mg/dL or 141 μmol/L (for male participants). 24. Exclude participants who have a history of alcohol abuse within the past 1 year (with weekly alcohol intake exceeding 21 units for men and 14 units per week for women (1 unit = 360 mL of beer; or 150 mL of wine; or 45 mL of liquor)) or a history of drug abuse.

25. Accept those who have received any of the following treatments:

  1. Within 12 weeks before the first administration of the drug:

    1. Intravenous immunoglobulin or plasma exchange therapy;
    2. Drugs known to have an impact on the cardiac conduction system (such as Class I or III anti-arrhythmic drugs);
    3. Other biologics except dupilumab.
  2. Within 4 weeks before administration, those who have used long-acting anticoagulant drugs (such as warfarin, dabigatran, etc.) or those who need continuous anticoagulant drug treatment (except aspirin \<= 100 mg/day).
  3. Within 1 week before the first administration of the investigational drug.

    1) Use antiplatelet drugs. Note: Based on the investigator's judgment, low-dose aspirin (dose \<= 100 mg, QD) for the purpose of preventing cardiovascular diseases is allowed; 26. Within 12 weeks before screening, those who have lost blood >= 400 mL (including trauma, blood collection, blood donation), or those who plan to donate blood during the study or within 1 month after the study.

    27. Due to other reasons, unable to complete this study or considered unsuitable by the investigator.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (estimated)

Study arms

  • Experimental
    The high-dose group of ZL-82 tablets

    Drug: The high-dose group of ZL-82 tablets

  • Experimental
    The low-dose group of ZL-82 tablets

    Drug: The low-dose group of ZL-82 tablets

  • Placebo comparator
    The placebo group

    Drug: The placebo group

Interventions

  • DrugThe high-dose group of ZL-82 tablets

    Participants will take the investigational drug orally for 16 weeks, 200mg each time , once a day.

  • DrugThe low-dose group of ZL-82 tablets

    Participants will take the investigational drug orally for 16 weeks, 100mg each time, once a day.

  • DrugThe placebo group

    The participants will take the investigational drug orally for 16 weeks, 2 tablets each time , once a day.

06

What researchers measure

Primary outcomes

  1. Compare the percentage changes in Eczema Area And Severity Index (EASI) scores from baseline between the ZL-82 tablets dose group and the placebo group.

    Time frame: At the 16th week

Secondary outcomes

  1. Compare respectively the percentage changes of EASI scores from baseline in the ZL-82 tablets dose group and the placebo group

    Time frame: At the 2nd, 4th, 8th and 12th weeks

  2. Compare respectively the proportions of participants in the ZL-82 tablets dose group and the placebo group whose EASI scores have improved by at least 50% (EASI-50), 75% (EASI-75) and 90% (EASI-90).

    Time frame: At the 2nd, 4th, 8th and 12th weeks

  3. Compare respectively the proportions of participants in the ZL-82 tablets dose group and the placebo group who had an IGA score of 0 or 1 and showed a 2-point improvement compared to the baseline in the Investigator's Global Assessment (IGA) method.

    Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks

  4. Compare the proportions of participants whose IGA scores improved by ≥ 2 points relative to the baseline in the ZL-82 tablet dose group and the placebo group respectively.

    Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks

  5. The weekly average peak pruritus numerical rating scale (PPNRS) scores of the ZL-82 tablets dose group and the placebo group were compared respectively to evaluate the changes from baseline.

    Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks

  6. Compare respectively the proportions of participants whose weekly average PPNRS scores relative to the baseline were ≥ 4 points in the ZL-82 tablets dose group and the placebo group.

    Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks

  7. Compare respectively the changes in the body surface area (BSA) affected by AD relative to the baseline in the ZL-82 tablets dose group and the placebo group.

    Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks

  8. The changes in Dermatology Life Quality Index (DLQI) relative to the baseline were compared respectively between the ZL-82 tablets dose group and the placebo group.

    Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks

  9. The changes in the scores of the Patient-Oriented Eczema Measure (POEM) scale, a self-assessment scale for eczema, of the participants in the ZL-82 tablets dose group and the placebo group relative to the baseline were compared respectively.

    Time frame: At the 2nd, 4th, 8th, 12th and 16th weeks

  10. health checkup

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.

  11. vital signs

    body temperature

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.

  12. laboratory tests results

    White blood cell

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  13. laboratory tests results

    urobilinogen

    Time frame: Screening period,Day141.If necessary, planned external visits to the participants must be conducted.

  14. PR interval

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  15. ZL-82 tablets blood drug concentration-time curve

    Time frame: Day1 Within 30 minutes before administration and 5minutes,15 minutes ,0.5 hours,1 hours,1.5 hours,2 hours,3 hours,4 hours,6 hours,8 hours after administration, Day15,Day29,Day57,Day85,Day113.

  16. PK parameters of ZL-82 tablets in blood(Cmax )

    Time frame: Day1 Within 30 minutes before administration and 5minutes,15 minutes ,0.5 hours,1 hours,1.5 hours,2 hours,3 hours,4 hours,6 hours,8 hours after administration

  17. The steady-state plasma concentration (Cmin, ss) of ZL-82 tablets before administration (Pre-dose)

    Time frame: Day1,Day15,Day29,Day57,Day85,Day113,If necessary, planned external visits to the participants must be conducted.

  18. vital signs

    blood pressure

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.

  19. vital signs

    respiration

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.

  20. vital signs

    pulse

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141.If necessary, planned external visits to the participants must be conducted.

  21. laboratory tests results

    Red blood cell

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  22. laboratory tests results

    platelet count

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  23. laboratory tests results

    Neutrophil granulocyte

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  24. laboratory tests results

    Total Protein

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  25. laboratory tests results

    Albumin

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  26. laboratory tests results

    total bilirubin

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  27. laboratory tests results

    direct bilirubin

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  28. laboratory tests results

    indirect bilirubin

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  29. laboratory tests results

    globulin

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  30. laboratory tests results

    alkaline phosphatase

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  31. laboratory tests results

    total cholesterol

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  32. laboratory tests results

    triglycerides

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  33. laboratory tests results

    high-density lipoprotein

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  34. laboratory tests results

    Low Density Lipoprotein

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  35. laboratory tests results

    fasting blood-glucose

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  36. laboratory tests results

    creatinine

    Time frame: Day-28 to Day-1,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  37. laboratory tests results

    urea nitrogen

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  38. laboratory tests results

    Uric Acid

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  39. laboratory tests results

    coagulation function

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  40. laboratory tests results

    urine test

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  41. QRS interval

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  42. QT/QTc interval

    Time frame: Screening period,Day1,Day15,Day29,Day57,Day85,Day113,Day141,If necessary, planned external visits to the participants must be conducted.

  43. PK parameters of ZL-82 tablets in blood(Tmax)

    Time frame: Day1 Within 30 minutes before administration and 5minutes,15 minutes ,0.5 hours,1 hours,1.5 hours,2 hours,3 hours,4 hours,6 hours,8 hours after administration

  44. adverse event

    Adverse events, serious adverse events, suspected and unexpected serious adverse reactions (SUSAR), priority adverse reactions, incidence of adverse reactions

    Time frame: From date of randomization until the date of completion of data collection, assessed up to 20 weeks

Other outcomes

  1. Eosinophil count

    Evaluate the changes in PD biomarkers of ZL-82 tablets in participants with moderate to severe AD.

    Time frame: Day1,Day15,Day29,Day57,Day85,Day113,If necessary, planned external visits to the participants must be conducted.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 22 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2025
First posted
Sep 26, 2025
StartActual
Feb 3, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07193589
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Feb 3, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Feb 4, 2026

Study contacts

Wang Fangmei
Contact
fangmei.wang@zenitar.cn
+8613808086495

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion